Research exec on Novo's diabetes pill: "I was convinced it would get me fired"
Lars Fogh Iversen, who was recently put in charge of Novo Nordisk's internal research, has been very involved in the company's work to develop a tablet version of the GLP-1 molecule semaglutide. But when the project began more than ten years ago, it did not look very promising and it would not have happened without teamwork across the organization, he says.
When Peter Kurtzhals - Novo's Head of R&D and right hand to the Executive Vice President and Chief Science Officer at Novo Nordisk, Mads Krogsgaard Thomsen - resigned earlier this year due to health reasons after 17 years on the post, his former field of responsibility was split into two.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
